The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
The outbreak led to urgent action by medical experts across the world to combat this devastating disease; including the setting up of trials of vaccines to stop the disease taking hold.
This global commitment to develop a vaccine against the disease suggested eight options, out of a starting pool of 15 candidates, should be evaluated in clinical trials worldwide by the end of 2015.
Professor Sanjeev Krishna, of St George’s University of London’s Institute for Infection and Immunity, said: “An unprecedented Ebola outbreak showed how it is possible for academics, non-governmental organisations, industry and funders to work effectively together very quickly in times of medical crisis. The results of the trial show how a vaccine could best be used to tackle this terrible disease effectively.
“We need a system of specialists, medical experts and organisers that maintains vigilance against outbreak diseases like Ebola.
“We should continue to improve ways to make, evaluate and deliver vaccines when they are needed, often in parts of the world lacking in infrastructure for diagnosing infections and providing treatments.”
He explained that considering the persistent replication of the vaccine which is called rVSV-?GP-ZEBOV in children and adolescents, further studies investigating lower doses in this population are warranted.
The vaccine contains a non-infectious portion of a gene from the Zaire Ebola virus. The St George’s researchers worked with colleagues on a vaccine trial in Gabon.
In addition, lower vaccine doses should be considered when boosting individuals with pre-existing antibodies to Ebolavirus glycoprotein, a finding that has emerged after the vaccine was tested in a country that has experienced Ebolavirus outbreaks in the past.
The vaccine was one of two being examined as a ‘candidate’ option by the World Health Organisation to identify urgently a vaccine to combat the Ebola virus outbreak in West Africa.
The clinical trial was led by colleagues at University of Tübingen in Germany, coordinated by Professor Peter Kremsner with their partner institute CERMEL in Lambaréné, Gabon.
The Latest on: Ebola vaccine
- China approves Ebola vaccine on October 22, 2017 at 8:13 pm
BEIJING. KAZINFORM China has approved a domestically developed Ebola vaccine, Xinhua refers to the China Food and Drug Administration (CFDA). The vaccine was developed by the Academy of Military Medical Sciences and CanSino Biologics INC. Its approval ... […]
- Ebola vaccine wins approval from regulators on October 20, 2017 at 11:19 pm
China's top food and drug authority announced on Friday that it has approved the country's first vaccine for Ebola virus disease. This makes China the third country, after the United States and Russia, with vaccines available for use to combat the deadly ... […]
- WSJ wisely reports on Ebola vaccines: ‘It is unknown…what antibody levels are needed to protect patients’ on October 17, 2017 at 9:13 am
This Wall Street Journal story reports on a New England Journal of Medicine-published study of the trial of two potential vaccines against Ebola disease. Overall, it’s a brief but well-constructed article on a much anticipated study of two Ebola ... […]
- Ebola vaccines from GSK, Merck elicit yearlong response, study finds on October 13, 2017 at 9:50 am
After initially setting out to test two vaccines on 28,000 volunteers during West Africa's deadly Ebola epidemic, a U.S.-Liberia research team had to dramatically reduce its aspirations when the outbreak started coming to an end. But the investigators have ... […]
- Ebola vaccines from Merck, Glaxo show promise on October 11, 2017 at 11:46 pm
The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease. […]
- PREVAIL I Ebola Vaccine Study Results Published on October 11, 2017 at 7:26 pm
Results from PREVAIL I—a large Ebola vaccine study that enrolled more than a thousand Liberians at Redemption Hospital in Monrovia during the first few months of 2015— have been published in the October 12 th issue of The New England Journal of Medicine. […]
- Two Ebola Vaccines Spur Lasting Immune Response on October 11, 2017 at 2:57 pm
WEDNESDAY, Oct. 11, 2017 (HealthDay News) -- Two experimental vaccines against the deadly Ebola virus are able to trigger an immune response that lasts for at least a year, a new clinical trial has found. Experts said the results give more support to one ... […]
- Two experimental Ebola vaccines show year-long promise on October 11, 2017 at 2:14 pm
Miami (AFP) - Two experimental vaccines against the Ebola virus have shown promise in protecting against the hemorrhagic fever for at least a year, according to the results of a major clinical trial published Wednesday. The report in the New England ... […]
- Experimental Ebola vaccines elicit year-long immune response on October 11, 2017 at 1:00 am
Results from a large randomized, placebo-controlled clinical trial in Liberia show that two candidate Ebola vaccines pose no major safety concerns and can elicit immune responses by one month after initial vaccination that last for at least one year. […]
- Ebola vaccine found safe for children, adults in Africa on October 9, 2017 at 12:29 am
Washington D.C.: The worst Ebola outbreak ended in 2016 after infecting more than 28,000 people and killing about 11,300 people worldwide. This outbreak forced the medical experts to take some serious action to combat the disease, which included setting up ... […]
via Google News and Bing News